Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, single arm phase II study.

Takeshi Kato,Masataka Ikeda,Atsuyo Ikeda,Junichi Hasegawa,Hirofumi Ota,Tatsushi Shingai,Masayoshi Yasui,Hitoshi Fujii,Yasuhiro Miyake,Mamoru Uemura,Chu Matsuda,Taroh Satoh,Tsunekazu Mizushima,Yuichiro Doki,Hidetoshi Eguchi

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, single arm phase II study.

2020

Takeshi Kato
Masataka Ikeda
Atsuyo Ikeda
Junichi Hasegawa
Hirofumi Ota
Tatsushi Shingai
Masayoshi Yasui
Hitoshi Fujii
Yasuhiro Miyake
Mamoru Uemura
Chu Matsuda
Taroh Satoh
Tsunekazu Mizushima
Yuichiro Doki
Hidetoshi Eguchi

e16039Background: Preoperative 5-FU-based chemoradiation is currently a standard treatment for advanced rectal cancer, particularly in Western countries. Although it reduced the local recurrence, i...

Keywords:

stage ii
Phases of clinical research
open label
Stage III Rectal Cancer
preoperative chemoradiotherapy
Surgery
Medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations